MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
BörsenkürzelMXCT
Name des UnternehmensMaxCyte Inc
IPO-datumMar 29, 2016
CEOMr. Maher Masoud, J.D.
Anzahl der mitarbeiter114
WertpapierartOrdinary Share
GeschäftsjahresendeMar 29
Addresse9713 Key West Avenue,
StadtROCKVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl20850
Telefon13015175556
Websitehttps://www.maxcyte.com/
BörsenkürzelMXCT
IPO-datumMar 29, 2016
CEOMr. Maher Masoud, J.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten